Draft Meeting Minutes

August 15, 2017
Embassy Suites Fort Lauderdale
1100 SE 17th Street
Ft Lauderdale, FL 33316
Contact Hotel: 954-315-1326
Call to Order - The meeting was called to order by the Committee Chair, Mr. Meshad, at 9:00 a.m.

Roll Call - Those present during the meeting included the following:

**Board Members**
- Gavin Meshad, Chair
- Debra Glass, BPharm
- Jeenu Philip, BPharm
- Michele Weizer, PharmD

**Attorneys**
- Board Counsel:
  - David Flynn, Assistant Attorney General
  - Lawrence Harris, Assistant Attorney General

**Board Staff:**
- C. Erica White, Executive Director
- Savada Knight, Regulatory Supervisor
- Jessica Hollingsworth, Government Analyst II

1. Opioid Epidemic and June 2017 Multi-Board Meeting Update

   **Discussion:**

   Mr. Meshad opened this topic for discussion with a brief history on why this committee was formed five years ago and its current purpose in assuring controlled substances are handled safely in Florida. He also discussed the importance of the committee continuing to address the opioid epidemic. Dr. Mesaros agreed that the board of Pharmacy plays a vital role in contributing to collaborative meetings with other professions and with other states and that the board should continue to take advantage of that.

2. Role of the Board of Pharmacy; Pharmacies; and Pharmacist

   **Discussion:**

   Mr. Meshad asked the board to develop recommendations and roles Pharmacy can play within those recommendations for the multi-board meeting in November. Mr. Philip expressed concern for health care practitioners who prescribe certain pain medications they aren’t properly trained on. Ms. Glass agreed and made the point of health care practitioners prescribing powerful medication initially instead of working through a process with the patient, beginning with less powerful medication and monitoring the patient for their need of more powerful medication. A
question was brought forth in what the role and responsibility is of the pharmacist in determining whether a prescription they have been given to fill is appropriate. Ms. Glass recommended requesting a partnership with the Medical Association in better utilizing PDMP. Ms. Weizer recommended presenting the issue how difficult it is to seek help for addiction. Dr. Mikhael added to this recommendation with examples of consequences that stem from cutting off addicts. A request was made to send recommendations and materials to the board office to combine for future board discussion and to have a conference call in September. Dr. Mesaros recommended asking subject-matter experts related to recommendations to present at the October meeting.

Michael Jackson, Executive Vice-President and CEO of the Florida Pharmacy Association, requested that the board research a recurring stream of funds to keep PDMP current and allow Florida to share the PDMP database across state lines.

Bob Parrado, a Florida Pharmacist, previous board member, and representative of the Hillsborough County Anti-Drug Alliance, recommended Gary White with the Medication Assistance Treatment (MAT) Program to present at the October board meeting. He also recommended for the .831 mandatory CE to be “live” instead of online so it is more effective.

John Hickman, with AstraZeneca, agreed that the CE on controlled substances has been effective but could be improved under Rule 62B16-27.831. He explained that improvements could include teaching pharmacists how to talk to patients about pain management. He also suggested allowing Pharmacists credit for medical education CEs and building a pharmacy guideline for pain management.

Gary Daylen, with Boca Raton Regional Hospital and representative of FSHP, confirmed that Mr. Meshad was correct in that the PDMP was renewed through HB 7097. He also clarified for Dr. Weizer that through HB 249, hospitals are required to report unintended drug overdoses to the Department of Health so they may utilize this information for drug enforcement.

Tom Cuomo, a Florida Pharmacist, gave his experience with a live CE and why it is better than online CEs. Mr. Meshad agreed with Mr. Cuomo in that a course is more effective when “live” and recommended making the controlled substance course live. Mr. Flynn stated he will research how this may be incorporated into rule.

The following recommendations were brought forth to research for the multi-board meeting, which will be discussed on a conference call in September:

- Limiting physician prescribing through DEA restrictions (will be researched by Glass)
- Ensuring physicians follow CDC guidelines for the process in prescribing through FL adoption or adaptation (will be researched by Glass)
- Updating the mandatory continuing education (CE) for prescribers for more effective learning (will be researched by Glass)
- Limiting initial fills (will be researched by Glass)
- Legal concerns and liability of pharmaceutical responsibility regarding manufacturing (will be researched by Bisaillon)
- REMS aspect of pharmaceutical responsibility regarding manufacturing (will be researched by Mesaros)

- Better use of PDMP, including mandatory checking of PDMP, funding of PDMP, and sharing PDMP data across state lines (will be researched by Mikhael)
  
  o Current balance of MQA Pharmacy trust-fund and how it can be utilized for the PDMP (trust fund aspect will be researched by Ms. Erica White)

- Mandatory counseling by pharmacists of all patients prescribed opiates, including facilitation of take-back or disposal of unused medication (will be researched by Alvarez)

- 499 drug take-back or disposal of unused medication (will be researched by Philip)

- Mandatory Escribe for controlled substances (will be researched by Philip)

- Raising awareness and access to rehab for addicts, increasing qualified/certified providers of rehabilitation (will be researched by Weizer)

- Mandatory CE for pharmacy controlled substances, making this CE a “live” requirement and part of initial licensure (will be researched by Meshad & Flynn)

- Letters to the deans of Florida schools of pharmacy and medicine. (will be researched by Meshad & Flynn)

- Research DEA rules for updates / changes (will be researched by Mesaros)

3. Collaborative Practice related to the Prescribing of Controlled Substances and Patient Management

Covered in Agenda Item #2

4. National Response to Opioid Epidemic

Covered in Agenda Item #2

5. Rule 64B16-27.831 – The Standards of Practice for the Filing of Controlled Substances Prescriptions; Electronic Prescribing; Mandatory Education.

The board agreed under agenda item #2 that making the CE live and interactive would make it more effective. Mr. Philip suggested incorporating education of the CDC guidelines into the CE. Mr. Flynn and Mr. Philip will work together in researching how to implement this.

6. Multi-Board Controlled Substance Workgroup – November 3, 2017

Covered in Agenda Item #2
7. Public Comment
Covered in Agenda Item #2

8. Adjournment

The meeting adjourned at 11:40 a.m.